InsiderTrades

Form 4 for GENB Generate Biomedicines, Inc.

Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-26 · accession 0001193125-26-085881 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2026-03-02 2026-03-02 GENB Bancel Stephane Dir C - Cnv Deriv — +724.2K 724.2K New —
D 2026-03-02 2026-02-26 GENB Bancel Stephane Dir A - Grant $0.00 +29.6K 29.6K New $0
DI 2026-03-02 2026-03-02 GENB Bancel Stephane Dir C - Cnv Deriv $0.00 -1.10M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-02 C A 724,160 — 724,160 I By OCHA LLC — — (F1) Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. (F2) Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
2 Derivative Stock Option (Right to Buy) 2026-02-26 A A 29,561 $0.00 29,561 D By OCHA LLC $16.00 · — to 2036-02-25 29,561 Common Stock (F2) Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. (F3) The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
3 Derivative Series A Preferred Stock 2026-03-02 C D 1,100,000 $0.00 0 I — · — to — 724,160 Common Stock (F1) Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date.